Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05492344
Other study ID # PEGASUS
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 9, 2022
Est. completion date November 1, 2026

Study information

Verified date January 2024
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact Jante S Sinnige, M.D.
Phone +31637405311
Email j.s.sinnige@amsterdamumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rationale Acute respiratory distress syndrome (ARDS) is a frequent cause of hypoxemic respiratory failure with a mortality rate of approximately 30%. The identification of ARDS phenotypes, based on focal or non-focal lung morphology, can be helpful to better target mechanical ventilation strategies of individual patients. Lung ultrasound (LUS) is a non-invasive tool that can accurately distinguish 'focal' from 'non-focal' lung morphology. The investigators hypothesize that LUS-guided personalized mechanical ventilation in ARDS patients will lead to a reduction in 90-day mortality compared to conventional mechanical ventilation.


Description:

Objective The aim of this study is to determine if personalized mechanical ventilation based on lung morphology assessed by LUS leads to a reduced mortality compared to conventional mechanical ventilation in ARDS patients. Study design The PEGASUS study is an investigator-initiated multicenter randomized clinical trial (RCT) with a predefined feasibility and safety evaluation after a pilot phase. Study population This study will include 538 consecutively admitted invasively ventilated adult intensive care unit (ICU) patients with moderate or severe ARDS. There will be a predefined feasibility and safety evaluation after inclusion of the first 80 patients. Intervention Patients will receive a LUS exam within 12 hours after diagnosis of ARDS to classify lung morphology as focal or non-focal ARDS. Immediately after the LUS exam patients will be randomly assigned to the intervention group, with personalized mechanical ventilation, or the control group, in which patients will receive standard care. Main study parameters/endpoints The primary endpoint is all cause mortality at day 90 (diagnosis of ARDS considered as day 0). Secondary outcomes are mortality at 28 days, ventilator free days (VFD) at day 28, ICU length of stay, ICU mortality, hospital length of stay, hospital mortality and number of complications (VAP, pneumothorax and need for rescue therapy). After a pilot phase, feasibility of LUS, correct interpretation of LUS images and correct application of the intervention within the safe limits of mechanical ventilation is evaluated to inform a stop-go decision. Nature and extent of the burden and risks associated with participation, benefit and group relatedness Patient burden and risks are low as the ventilation methods in this study are already commonly used in ICU practice; the collection of general data from hospital charts and (electronic) medical records systems causes no harm to the patients; LUS is not uncomfortable.


Recruitment information / eligibility

Status Recruiting
Enrollment 538
Est. completion date November 1, 2026
Est. primary completion date August 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Admitted to a participating ICU, - invasively ventilated and - fulfil the Berlin criteria for moderate or severe ARDS. Exclusion Criteria: - Age under 18, - participation in other interventional studies with conflicting endpoints, - conditions in which LUS is not feasible or possible (e.g. subcutaneous emphysema, morbid obesity or wounds), - mechanical ventilation for longer than 7 consecutive days in the past 30 days, - history of ARDS in the previous month, - body-mass index higher than 40 kg/m², - intracranial hypertension, - broncho-pleural fistula, - chronic respiratory diseases requiring long-term oxygen therapy or respiratory support, - pulmonary fibrosis with a vital capacity < 50% (severe or very severe), - previously randomized in the PEGASUS study - ECMO - patients who are moribund or facing end of life and - no informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Personalized ventilation
Patients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings: Positive end-expiratory pressure (PEEP) = 9 cm water (H2O) Tidal volume: 6 to 8 mL/kg predicted body weight (PBW) Daily prone positioning LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol. Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings: PEEP = 15 cm H2O Tidal volume: 4 to 6 mL/kg PBW Daily recruitment maneuver
Standard care
Patient who are randomized in the control group will receive standard care Tidal volume: 6 mL/kg PBW PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is < 150 mmHg

Locations

Country Name City State
Belgium Chu-Brugmann Bruxelles
Denmark Bispebjerg Hospital Copenhagen
Denmark Nordsjaellands Hospital Hillerød
Greece Evaggelismos Hospital Athens
Ireland Galway University Hospitals Galway
Italy Ospedale Generale Regionale F. Miulli Acquaviva Delle Fonti Bari
Italy Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari Bari
Netherlands Amsterdam UMC, location AMC Amsterdam Noord-Holland
Netherlands Amsterdam UMC, location VUmc Amsterdam Noord-Holland
Poland Centralny Szpital Kliniczny MSWiA Warsaw

Sponsors (1)

Lead Sponsor Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Countries where clinical trial is conducted

Belgium,  Denmark,  Greece,  Ireland,  Italy,  Netherlands,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary All-cause mortality Any death during ICU- or hospital-stay at day 90 90 days after inclusion
Secondary All-cause mortality Any death during ICU- or hospital-stay at day 28 28 days after inclusion
Secondary Ventilator free days Duration of ventilation in survivors 28 days after inclusion
Secondary ICU length of stay Length of stay in the intensive care unit 90 days after inclusion
Secondary ICU mortality Mortality in the ICU 90 days after inclusion
Secondary Hospital length of stay Length of stay in the hospital 90 days after inclusion
Secondary Hospital mortality Mortality in the hospital 90 days after inclusion
Secondary Number of patients with Complications Ventilator associated pneumonia and pneumothorax 90 days after inclusion
Secondary Number of patients with Adjunctive therapies Extracorporeal membrane oxygenation (ECMO), recruitment, prone position 90 days after inclusion
Secondary Number of patients with Rescue therapies Inhaled vasodilators, airway pressure release ventilation 90 days after inclusion
See also
  Status Clinical Trial Phase
Completed NCT05921656 - Construction and Evaluation of Airway Leakage Risk Model of Patients With Endotracheal Tube
Recruiting NCT03941002 - Continuous Evaluation of Diaphragm Function N/A
Withdrawn NCT04288076 - The Brain and Lung Interaction (BALI) Study N/A
Completed NCT03031860 - Semi-quantitative Cough Strength Score (SCSS) N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Completed NCT02312869 - Local Assessment of Management of Burn Patients N/A
Completed NCT01885442 - TryCYCLE: A Pilot Study of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients N/A
Completed NCT01204281 - Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients Phase 4
Terminated NCT01059929 - Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU) Phase 4
Completed NCT00824239 - Intermittent Sedation Versus Daily Interruption of Sedation in Mechanically Ventilated Patients Phase 3
Completed NCT00529347 - Mechanical Ventilation Controlled by the Electrical Activity of the Patient's Diaphragm - Effects of Changes in Ventilator Parameters on Breathing Pattern Phase 1
Unknown status NCT00260676 - Protective Ventilatory Strategy in Potential Organ Donors Phase 3
Terminated NCT00205517 - Sedation and Psychopharmacology in Critical Care N/A
Completed NCT03281785 - Ultrasound of Diaphragmatic Musculature in Mechanically Ventilated Patients. N/A
Recruiting NCT04110613 - RCT: Early Feeding After PEG Placement N/A
Completed NCT04410783 - The Emergency Department Sedation Pilot Trial N/A
Recruiting NCT04821453 - NAVA vs. CMV Crossover in Severe BPD N/A
Completed NCT03930147 - Ventilation With ASV Mode in Children N/A
Recruiting NCT05029167 - REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study) N/A
Recruiting NCT04849039 - Lung Microbiota and VAP Development (PULMIVAP)